Patient-based Care Versus Standard Care for Patients With hEDS/HSD and Multidirectional Shoulder Instability
Effectiveness of a 6-month Home-based Exercise Program for Treating Shoulder Instability in Patients With Hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD): A Pilot Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgium, 9000
- Ghent University, Department of Rehabilitation Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- 18-65 years
- Patients diagnosed by a medical doctor with generalized HSD or hEDS, according to the diagnostic criteria for hEDS and HSD as stated in the recently published international classification for the Ehlers-Danlos syndromes
- Patients diagnosed with multidirctional shoulder instability (MDI): The diagnosis of MDI was confirmed when 1) patients reported symptoms of shoulder instability in daily life (e.g. recurrent subluxations) without a traumatic onset; 2) patients scored positive on shoulder laxity and instability tests (i.e. sulcus sign, anterior and posterior load and shift, posterior jerk, Gagey hyperabduction test, passive and active external rotation in supine, apprehension and relocation test) in at least two directions; 3) patients had shoulder pain for at least three months prior to the study.
Exclusion Criteria:
- pregnancy during study participation
- patients who started a new physiotherapeutic treatment in the 2 weeks prior to the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Evidence-based tailored care (group A)
Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
|
exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
|
|
Active Comparator: Evidence-based standard care (group B)
This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
|
The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Western Ontario Shoulder Instability Index (WOSI)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks, in order to assess the change in WOSI from baseline to 6 weeks, 12 weeks, and 24 weeks
|
The WOSI is a responsive patient-reported and disease-specific tool, designed to be used as the primary outcome measure in clinical trials that assess treatments for patients with shoulder instability.
Range 0 - 2100 points.
Higher scores express worse status.
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks, in order to assess the change in WOSI from baseline to 6 weeks, 12 weeks, and 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Disabilities of the Arm Shoulder and Hand (DASH)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
The DASH is a region-specific questionnaire of upper extremity disability (range 0-100).
Higher scores express worse status
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
|
The Tampa Scale for Kinesiophobia (TSK)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
The TSK is one of the most frequently used measures for evaluating general pain-related fear of movement.
Range 17 - 68 points.
Higher scores express worse status.
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
|
The Patient-Specific Functional Scale (PSFS)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
The PSFS is a patient-rated outcome measure designed to evaluate functional change.
Patients were asked to identify 3 activities they were having difficulty with as a result of their shoulder instability, and to rate each activity on an 11-point Likert scale (0 = impossible to perform the activity; 10 = able to perform the activity without complaints or help).
At each follow-up moment, the same 3 activities were rated.
The total PSFS score was calculated by adding the scores for the 3 activities.
Range 0-30 points.
Higher scores express better status.
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
|
The Global Rating of Change (GROC)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
The GROC is a transitional scale used to quantify patient-perceived improvement.
It can be used to assess the results of treatment since it defines the change in health status as perceived by the patient.
We asked patients to rate whether or how much their shoulder has changed since the beginning of the study on a 11 point numerical scale ('How would you describe the change in your shoulder since the beginning of the treatment program?' with -5= a lot worse; 0 = unchanged; +5= fully recovered).
Range -5 to 5 points.
Higher scores express better status.
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
|
Pain pressure thresholds (PPT)
Time Frame: Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
PPTs were measured on five locations around the shoulder (local PPTs).
Additionally, a distal PPT was measured at the midpoint of the quadriceps muscle.
|
Measured at baseline, 6 weeks, 12 weeks and 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fransiska Malfait, Prof. Dr., Centre of Medical Genetics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Disease
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Hemostatic Disorders
- Skin Diseases, Genetic
- Skin Abnormalities
- Collagen Diseases
- Syndrome
- Ehlers-Danlos Syndrome
Other Study ID Numbers
Other Study ID Numbers
- B670201939864
- BOF17/DOC/220 (Other Grant/Funding Number: Bijzonder Onderzoeksfonds (BOF))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.